Introduction
The p53 tumor suppressor has a key role in the cellular response to diverse forms of stress (Vousden and Lu, 2002) . Under normal conditions, p53 is expressed at low levels because of negative feedback regulation by MDM2 (Haupt et al., 1997; Kubbutat et al., 1997) . Upon cellular stress, p53 is stabilized and transactivates a number of genes that promote cell-cycle arrest (GADD45, p21, 14-3-3s) and apoptosis (Bax, Noxa, Puma) (Vousden and Lu, 2002) . p53 can transrepress some anti-apoptotic genes (BCL2, hTERT) (Mirza et al., 2003; Rahman et al., 2005) . Furthermore, p53 has trancription-independent pro-apoptotic and antiautophagic activity in the cytoplasm where it localizes to the mitochondria (reviewed by Green and Kroemer, 2009) . p53 is also involved in processes such as DNA repair (Livneh, 2006) , cellular senescence (Xue et al., 2007) , and metabolism (Vousden and Ryan, 2009) .
Alterations in the p53 gene, mostly missense mutations, are found in about half of all human tumors (Olivier et al., 2002) . These mutations are clustered within the DNA-binding domain and thus impair p53's ability to function as a transcription factor. The loss of wild-type p53 tumor suppressor activity as well as the acquisition of novel functions (so called gain-of-function) attributed to some p53 mutants, often counteracts the effect of cancer treatment, as many anti-cancer drugs attack tumors by activating p53-dependent apoptosis (Bunz et al., 1999; Andersson et al., 2005) . Gain-offunction effects include the ability of mutant p53 to transactivate illegitimate targets such as MDR1, vascular endothelial growth factor (VEGF), and c-myc, and inactivate other members of the p53 family by heterodimerization (Cadwell and Zambetti, 2001; Gaiddon et al., 2001) .
Mutant p53 is often expressed at high levels in tumors. Therefore, therapeutic reactivation of mutant p53 should trigger massive apoptosis and allow efficient eradication of tumor cells in vivo. We have shown earlier that PRIMA-1 restores wild-type properties to mutant p53, that is transactivation of some of p53's target genes (p21, MDM2, and Bax), and induces apoptosis in a mutant p53-dependent manner in vitro and in vivo (Bykov et al., 2002; Zache et al., 2008) . We also showed that PRIMA-1 triggers apoptosis through the mitochondrial pathway and activation of caspase-2, -3, and -9 (Shen et al., 2008) . Others have found that Baxdependent apoptosis induced by PRIMA-1 is mutant p53-dependent but transcription-independent (Chipuk et al., 2003) . Recently, we have shown that PRIMA-1 is converted to reactive products with Michael acceptor activity that bind covalently to the p53 core domain, and that such modification is critical for reactivation of mutant p53 (Lambert et al., 2009) .
Here, we have investigated how rescue of mutant p53 by PRIMA-1 MET , an analog of PRIMA-1 (Bykov et al., 2005) , affects global gene transcription. We found that PRIMA-1
MET affects transcription mainly in the mutant p53-expressing cells. Our results indicate that PRIMA-1 induces cell death through multiple pathways encompassing transcription-dependent and -independent signaling. These results provide significant novel insights into the mechanisms of PRIMA-1 MET -induced cell death, and should facilitate the design of even more potent mutant p53-reactivating compounds.
Results

PRIMA-1
MET affects the transcriptome in a mutant p53-dependent manner The mutant p53-expressing Saos-2-His273 cells were treated with 37 mM PRIMA-1
MET for 6 and 12 h. This concentration was chosen based on our earlier studies, as it gives a robust mutant p53-dependent apoptosis ( Figure 1a Table 2 ). None of the identified genes were affected in both cell lines. We focused our further analysis on the gene list generated from the Saos-2-His273 cells. We selected significantly up-or downregulated genes that are involved in different pathways, including cell-cycle regulation and apoptosis, and analyzed their expression by real-time PCR. We confirmed the microarray data for 11 genes, including Noxa, GADD45B, Yin Yang 1 (YY1), PTCH1, and XBP1.
Three genes induced in Saos-2-His273 cells, Scotin, Noxa, and YY1, are known wild-type p53 targets. Sequence analysis showed that 23 of the identified genes contain putative p53-binding sites (Wang et al., 2001; Hoh et al., 2002; Ceribelli et al., 2006;  Table 2 ). However, classical p53 transcription targets, such as p21, MDM2, and Bax, were not affected by PRIMA-1 MET in our microarray analysis. As we and others have observed earlier that PRIMA-1 MET induces the pro-apoptotic p53 target Bax at the protein level (Chipuk et al., 2003; Bykov et al., 2005) , we investigated Bax mRNA expression using a more sensitive method, real-time PCR. This showed a 2.43 ± 0.92-fold upregulation of Bax mRNA in Saos-2-His273 cells at 6 h, but not in the p53 null Saos-2 cells (0.80±0.24-fold change; data not shown). Importantly, PRIMA-1 MET did not affect expression of any p53 target genes in Saos-2 cells according to the microarray data. Overall, we conclude that PRIMA-1 MET significantly affects the transcriptome in a mutant p53-dependent manner, and induces transcription of a subset of p53 target genes.
MET affects transcription of cell-cycle arrest and apoptosis-related genes in Saos-2-His273 cells Next, we analyzed our data set using the Ingenuity software to identify cellular pathways that were affected after exposure of Saos-2-His273 cells to PRIMA-1 MET . At 6 h of treatment, the cell cycle and proliferation pathways were the most affected, whereas genes involved in the cell death pathway were most affected at 12 h. These findings are in full agreement with the observed changes in cell-cycle distribution according to propidium iodide staining and flow cytometry (Figure 1a ). Although no cell-cycle changes in Saos-2 cells were observed after PRIMA-1 MET treatment, a prominent G2 arrest and an increased sub-G1 population were detected in Saos-2-His273 after 48 h exposure to 37 mM of PRIMA-1 MET . All genes identified in our microarray analysis and genes involved in the cell cycle and proliferation or cell death pathways are listed in Table 1 . GADD45B and 14-3-3g, both of which have roles in regulation of cell-cycle progression and cell growth, were examined further. Upregulation of GADD45B mRNA was detected by both the microarray analysis (3.05 ± 0.66-fold induction) and real-time PCR (1.44±0.01-fold induction) (Figure 1b) . For 14-3-3g, we observed a 1.80 ± 0.17-fold induction of mRNA levels on the microarray but this could not be confirmed by real-time PCR (Figure 1b) . However, we did detect a significant induction at the protein level of up to five times in Saos-2-His273 cells by both western blotting and immunostaining (Figure 1c ; data not shown), whereas no such changes could be seen in Saos-2 cells. Noxa is involved in apoptosis and is also known to be p53 transcriptional target. Noxa showed 3.18±0.73-fold upregulation at the mRNA level at 12 h according to the microarray. This was confirmed by real-time PCR PRIMA-1 induces ER stress-mediated apoptosis JMR Lambert et al expression of 14-3-3 and Noxa. As shown in Figure 1e , expression of exogenous wild-type p53 in these cells led to upregulation of both 14-3-3 and Noxa to levels comparable to those observed in PRIMA-1 MET -treated Saos-2-His273 cells, although Noxa was induced more efficiently by wild-type p53. Next, we examined the expression of 14-3-3 and Noxa in SW480 colon carcinoma cells that carry endogenous His273 mutant p53, and confirmed upregulation of Noxa, 14-3-3g, and GADD45 mRNA after PRIMA-1 MET treatment ( Figure 1f ). Altogether these results show that the reactivation of mutant p53 by PRIMA-1 MET leads to enhanced expression of genes involved in cell-cycle regulation and apoptosis.
Disruption of the cytoskeleton after PRIMA-1
MET treatment
We observed that PRIMA-1 MET induces changes in expression of several genes involved in the rearrangement of the cytoskeleton in a mutant p53-dependent manner, including WIRE, CNN2, Vinculin, and Supervillin. PRIMA-1 MET induced characteristic apoptosisrelated cytoskeleton rearrangements. The degradation of actin filaments in Saos-2-His273 cells was evident only after 24 h and was concentration dependent (Figure 2 ). At 25 mM, an actin ring was formed at the cell borders, accompanied by the formation of membrane blebs and clumps. At 50 mM, at a later stage of apoptosis, the actin cytoskeleton was fully disrupted, with only some actin clumps remaining (Figure 2 ). No such distortion of the cytoskeleton was observed in parental p53 null Saos-2 cells (Figure 2 ). We observed the reduction of filaments in Saos-2 cells only with substantially higher concentrations of PRIMA-1 MET (not shown). These data suggest that mutant p53-dependent apoptosis induced by PRIMA-1
MET involves cytoskeleton rearrangements, which are hallmarks of the activated cell death program.
PRIMA-1 MET treatment induces endoplasmic reticulum stress
One of the genes that were strongly upregulated in Saos-2-His273 cells on PRIMA-1 MET treatment is XBP1. We observed a 2.36±0.39-fold increase at 12 h. These results were confirmed by real-time PCR, which showed a 2.36 ± 0.29-fold induction at 12 h ( Figure 3a ). XBP1 is associated with endoplasmic reticulum (ER) stress (Yoshida et al., 2001) . Its mRNA is cleaved on ER stress, giving rise to a spliced form, (S) XBP1, that activates the unfolded protein response. Figure 3b shows that PRIMA-1 MET treatment induced cleavage of XBP1 mRNA more prominently in the mutant p53-expressing cells. Thapsigargin, which blocks the ER Ca 2 þ pump by inhibiting the Ca 2 þ -ATPase and thus elicits ER stress (Inesi and Sagara, 1992) , was used as a positive control to induce XBP1 cleavage. Moreover, we detected XBP1 cleavage in SW480 colon carcinoma cells carrying mutant p53 (Figure 3b ). Interestingly, we found that DNAJB2, an Hsp40-like downstream protein target of XBP1, was upregulated after PRIMA-1 MET treatment (Figure 3c ), although this occurred in both Saos-2 and Saos-2-His273 cells. Finally, we tested whether PRIMA-1 MET treatment would lead to an accumulation of unfolded proteins, the fundamental characteristic of ER stress (Lai et al., 2007) . GRP78, another protein involved in ER stress, is known to bind unfolded proteins accumulating in the ER . We treated cells with PRIMA-1 MET , immunoprecipitated GRP78, and resolved proteins by PAGE followed by silver staining. Densitometry showed a 20% increase in total proteins co-immunoprecipitated with GRP78 in Saos-2-His273 treated with PRIMA-1 MET , whereas PRIMA-1 induces ER stress-mediated apoptosis JMR Lambert et al no increase was observed in the p53 null Saos-2 cells (data not shown). Thus, the observed cleavage of XBP1 and accumulation of unfolded proteins, along with the upregulation of Noxa, which is involved in ER stress-induced cell death, indicate that PRIMA-1 MET triggers ER stress.
Discussion
PRIMA-1 MET has been shown to restore wild-type conformation to mutant p53, resulting in upregulation of p53 targets such as p21, MDM2, and Bax (Bykov et al., 2002 (Bykov et al., , 2005 . We have also shown that PRIMA-1 induces apoptosis through activation of caspase-2 and the intrinsic mitochondrial cell death pathway (Shen et al., 2008) . Here, we have investigated the effects of mutant p53 reactivation on global transcription. Treatment with PRIMA-1 MET led to mutant p53-dependent induction of genes involved in regulation of cell growth and survival, including 14-3-3g (YWHAG) and GADD45B that inhibit cell-cycle progression, and Noxa that promotes apoptosis. These results are fully consistent with the documented ability of PRIMA-1 MET to inhibit growth and induce apoptosis in human and mouse tumor cells in a mutant p53-dependent manner.
A significant fraction, 23 out of 185 (12.4%), of the identified genes carry putative p53-binding sites (Table 2 ). This is in agreement with our earlier findings that PRIMA-1 MET restores wild-type conformation and DNA binding to mutant p53. Nonetheless, we did not detect any major changes in expression of classical p53 target genes such as p21 and MDM2, although upregulation of both genes was observed earlier at the protein level in PRIMA-1 or PRIMA-1 MET -treated cells (Bykov et al., 2002 (Bykov et al., , 2005 . A plausible explanation for this discrepancy is that mRNAs for these genes are only transiently upregulated between the 6 and 12 h time points used in our study. It should also be noted that although our microarray analysis failed to detect increased expression of Bax, real-time PCR showed a marked mutant p53-dependent induction (data not shown). The correlation between Affymetrix and realtime PCR data was reported to be about 85%; however, weakly expressed mRNA showed a lower correlation (Rogojina et al., 2003) . This may explain some of the observed differences between our Affymetrix and realtime PCR data. Moreover, YY1 has been reported to bind to p53-target sites in a sequence-dependent manner and inhibit transcription of some p53 target genes, such as p21 but not Bax (Gronroos et al., 2004; Yakovleva et al., 2004) . Thus, the increased expression of YY1 favors apoptosis.
We observed a marked mutant p53-dependent change in expression of genes that are functionally related to the cytoskeleton, including upregulation of WIRE and downregulation of Supervillin. Ectopic expression of the WASP-binding protein, WIRE, causes actin cytoskeleton redistribution and actin depolymerization (Hossain et al., 2003) . Overexpression of supervillin, an F-actin-binding protein, results in increased levels of F-actin (Wulfkuhle et al., 1999) . Upregulation of WIRE and downregulation of Supervillin may account for the observed reduction of filamentous actin or depolymerization in the PRIMA-1 MET -treated mutant p53-expressing cells.
It is particularly noteworthy that several genes associated with ER stress were induced by PRIMA-1 MET , such as XBP1, Noxa, and DNAJB2 (Abcouwer et al., 2002; Westhoff et al., 2005; Li et al., 2006) . This indicates that PRIMA-1 MET somehow affects protein folding in the cell, leading to activtion of the ER stress pathway. This notion is further supported by the observed cleavage of XBP1 mRNA. Moreover, an 
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earlier study showed that PRIMA-1 MET increases the level of HSP70, a chaperone involved in protein folding (Rokaeus et al., 2007) , suggesting an increase in the unfolded protein fraction on PRIMA-1 MET treatment. Interestingly, XBP1 contains a putative p53 response element, consistent with the involvement of p53 in ER stress (Ceribelli et al., 2006) and the upregulation of XBP1 by PRIMA-1 MET in this study.
Recently, we have shown that PRIMA-1, through its conversion products, modifies mutant p53 protein by binding to thiol groups in the core domain (Lambert et al., 2009) . Such modification of p53 per se was sufficient to induce apoptosis in tumor cells. However, our data indicate that reactive conversion products of PRIMA-1 could potentially modify a number of other proteins in cells, including other members of the p53 family, such as p63 and p73. Mutant p53 has been shown to bind and inactivate p63 and p73 (Di Como et al., 1999; Strano et al., 2002) . It is conceivable that modifications of p63 or p73 could disrupt mutant p53 binding and thus trigger p63/p73-dependent apoptosis. PRIMA-1-modified p63 or p73 may also have its own set of target genes. (Lambert et al., 2009) , consistent with restoration of wild-type properties to mutant p53 because wild-type p53 can promote ROS on severe stress, leading to apoptosis (Johnson et al., 1996; Polyak et al., 1997; Sablina et al., 2005) . As ROS are known inducers of ER stress (He et al., 2008) , our results suggest that PRIMA-1 MET triggers the ER stress pathway at least partially through mutant p53-dependent induction of ROS. Our data also suggest that modification of many proteins in PRIMA-1-treated cells has a relatively small impact on cell survival, in agreement with our earlier findings that PRIMA-1-modified albumin does not induce apoptosis when introduced in tumor cells (Lambert et al., 2009) . Therefore, it is likely that PRIMA-1 targets only a limited number of cellular proteins that are capable of triggering cell death signaling pathways, and that one of these targets is mutant p53.
Furthermore, Bax and Bak are known to interact and activate IRE-1, leading to increased ER stress signaling (Hetz et al., 2006) . Therefore, we suggest that PRIMA-1 MET activates the ER stress signaling cascade through both ROS induction and Bax-mediated IRE-1 activation. ER stress can trigger apoptosis through two main pathways, either through the mitochondrial pathway involving Bcl-2 family proteins (Li et al., 2006) or through JNK through its activation by the IRE-1 kinase (Urano et al., 2000) . This may explain why earlier studies have shown PRIMA-1 MET induced apoptosis through Bax and the mitochondrial pathway (Chipuk et al., 2003; Wang et al., 2007; Shen et al., 2008) or the JNK pathway in a mutant p53-dependent manner (Li et al., 2005) .
VEGF expression is known to be downregulated by wild-type p53 (Mukhopadhyay et al., 1995) . We found a PRIMA-1 induces ER stress-mediated apoptosis JMR Lambert et al strong upregulation of this gene after reactivation of mutant p53 by PRIMA-1 MET . However, VEGF mRNA expression is rapidly increased after exposure to chemical inducers of ER stress (Abcouwer et al., 2002) . Thus, the increase observed here may not be directly p53 dependent but rather a response to PRIMA-1 MET -induced ER stress. In conclusion, our microarray analysis demonstrates that PRIMA-1 MET has profound impact on global gene expression in a mutant p53-dependent manner. PRIMA-1 MET treatment leads to induction of series of p53 target genes that promote cell-cycle arrest and apoptosis. We have uncovered an ER stress signaling pathway triggered by PRIMA-1 MET in mutant p53-expressing cells. Interestingly, ER stress-induced apoptosis can be achieved through either the JNK pathway or the mitochondrial pathway. Thus, we have shown that PRIMA-1 restores both transcription-dependent and transcription-independent pro-apoptotic activity to mutant p53. This is in agreement with the notion that p53 can induce apoptosis also in a transcription-independent manner (Caelles et al., 1994) . Activation of multiple apoptotic pathways not only allows a robust apoptotic response, but also reduces the risk of emerging drugresistant variants. Thus, our results have identified novel molecular mechanisms for PRIMA-1-induced cell death and may facilitate the design for novel anti-cancer drugs, and ultimately more efficient cancer therapy.
Materials and methods
Cell lines and reagents
The human Saos-2 osteosarcoma and H1299 lung adenocarcinoma cell lines are p53 null. Their sublines Saos-2-His273 and H1299-His175 are stably transfected with the tetracyclineregulated His273 or His175 mutant p53 expression constructs (Tet-Off), respectively. The human SW480 colon adenocarcinoma line expresses endogenous His273/Ser309 mutant p53. The human HCT116 p53 þ / þ colon carcinoma line harbors wild-type p53. Its sublines HCT116 p53 À/À and HCT116 p53
lack p53 or express Trp248 mutant p53, respectively. All cells were grown at 37 1C under 5% CO 2 in Iscove's-modified Dulbecco's medium containing 10% FBS, 2 mM L-glutamine and 40 mg/ml gentamycin. Wild-type p53 plasmid carrying the full-length p53 cDNA sequence inserted into the pCMV expression vector was generously provided by Dr Bert Vogelstein. The transient transfection experiments were performed with Lipofectamine 2000 according to the manufacturer's recommendations (Invitrogen Life Technologies, Breda, the Netherlands). For all experiments, cells were plated at a density of 15 000 cells/cm 2 and were incubated overnight before treatment.
Microarrays
Cells were treated with PRIMA-1 MET for 6 and 12 h. RNA was extracted using RNeasy Mini Kit (Qiagen, Solna, Sweden) according to manufacturer's instructions. The optical density at 260/280 nm was between 1.9-2.1. Double-stranded cDNA was synthesized with 1 mg of total RNA using the SuperScript Abbreviation: YY1, Yin Yang 1.
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Choice system (Invitrogen, Stockholm, Sweden). T7-(dT24) oligomer was used for priming the first-strand cDNA synthesis. The resulting cDNA was purified using the sample clean up kit (Affymetrix Inc., Santa Clara, CA, USA). The cDNA pellet was collected and dissolved in an appropriate volume. Using cDNA as the template, cRNA was synthesized using an in vitro transcription kit (Affymetrix Inc.). Biotinylated-11-CTP and 16-UTP ribonucleotides (Affymetrix Inc.) were added to the reaction as labeling reagents. in vitro transcription reactions were carried out at 37 1C for 16 h and, the labeled cRNA was purified using the sample clean up kit (Affymetrix Inc.). The cRNA was fragmented in a fragmentation buffer (40 mmol/l Tris-acetate, pH 8.1, 100 mmol/l KOAc, 30 mmol/l MgOAc) for 35 min at 94 1C. Fragmented cRNA (15 mg/probe array) was hybridized with the human U133 2.0 plus GeneChip array at 45 1C for 18 h in a hybridization oven with constant rotation (60 r.p.m.). The chips were washed and stained using the Affymetrix fluidics stations. Staining was performed using streptavidin phycoerythrin conjugate (SAPE; Molecular Probes, Eugene, OR, USA) followed by the addition of a biotinylated anti-streptavidin antibody (Vector Laboratories, Burlingame, CA, USA), and finally with streptavidin phycoerythrin conjugate. Probe arrays were scanned using GeneChip Scanner 3000 with AutoLoader (Affymetrix Inc.). The scanned images were inspected and analyzed using established quality control criteria.
Data analysis
Comparative analysis between expression profiles for Affymetrix experiments was carried out using GeneSpring software version 7.3 (Silicon Genetics, Redwood City, CA, USA). The 'Cross gene error model for deviation from 1.0' was active. Gene expression data were normalized in two ways: 'per chip normalization' and 'per gene normalization'. For 'per chip normalization', all expression data on a chip are normalized to the 50th percentile of all values on that chip. For 'per gene normalization', the data for a given gene are normalized to the median expression level of that gene across all samples. The data sets were then assigned to six groups for either experiment Saos-2 (0, 6, and 12 h) or Saos-2-His273 (0, 6, and 12 h). The expression profiles from three independent experiments were compared using ANOVA (parametric test, assume variances equal) to identify genes that were differentially expressed between the six groups. For sample clustering, standard correlation was applied to measure the similarity of the expression pattern between different samples. Gene lists were made with genes that were either induced or suppressed >1.3-fold between treatments and time points. The genes were categorized according to their biological functions as described in Gene Spring, Ingenuity and GeneCards. data accesion number online: GSE15658 (http://www.ncbi.nlm.nih.gov/geo/ query/acc.cgi?acc ¼ GSE15658)
Real-time PCR Cells were treated with PRIMA-1 MET and were collected after 6 and 12 h, RNA was extracted and cDNA was synthesized, as described above. cDNA of 12 ng was added to 50 ml of Taqman Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA) and total volume was adjusted to 100 ml with RNasefree water. Samples were loaded into the 384-wells Taqman Low Density Array (Applied Biosystems). The following probes were available on the array: Hs00820472_m1 (EIF5), Hs00177066_m1 (MAPK1), Hs00192541_m1 (RAD23A), Hs00169587_m1 (GADD45B), Hs00370193_m1 (WIPF2/ WIRE), Hs00560402_m1 (PMAIP1/Noxa), Hs00176092_m1 (STK11), Hs01579127_m1 (Scotin) Hs01113553_mH (YWHAG/14-3-3g), Hs00159048_m1 (MAP4), Hs00701790_s1 (UBE2D3), Hs00231936_m1 (XBP-1), Hs00231533_m1 (YY1), Hs00367225_m1 (CARD10), Hs00204044_m1 (ASF1A), Hs00198807_m1 (DNAJB2), Hs00266026_m1 (IGFBP7), Hs00854264_s1 (CNN2), Hs00269428_m1 (PEA15), Hs00173626_m1 (VEGFA), Hs00181117_m1 (PTCH1), and Hs99999901_s1 (18S) (Applied Biosystems).
Amplification started with 2 min at 50 1C and 10 min at 95 1C, and was followed by 40 cycles with 15 s denaturation at 95 1C and 1 min annealing/extension at 60 1C. Reactions were run on the ABI PRISM 7900HT Fast real-time PCR System (Applied Biosystems). Results were analyzed with the comparative Ct method using 18S as gene of reference. Real time for Bax was run separately using the standard protocol and the Taqman Gene Expression Assay Hs00414514_m1 (BAX) and Hs99999905_m1 (GAPDH) (Applied Biosystems).
Retrotranscriptase PCR for XBP1 Cells were treated with PRIMA-1 MET for 12 h. Then cells were collected and RNA was extracted as described above. Samples were incubated with recombinant DNase (Roche Applied Science, Bromma, Sweden). cDNA was synthesized as described above but by using random primers instead of OligodT. cDNA of 50 ng was amplified with TopTaq PRIMA-1 MET reactivates mutant p53, which triggers the mitochondrial apoptosis pathway through Puma and Bax. Reactivation of mutant p53 is followed by the production of ROS that can induce ER stress, and as a consequence, the accumulation of unfolded proteins in the ER. During stress, GRP78 binds unfolded proteins and releases IRE-1, which is dimerized. Activated IRE-1 leads to the cleavage of XBP1 mRNA and the activation of the JNK pathway and apoptosis. Bax, which is upregulated after PRIMA-1 MET treatment, can directly activate IRE-1. During sustained ER stress, Noxa is induced in a mutant p53-dependent manner. We do not exclude that PRIMA-1 may have direct effects on protein folding/ER stress. The downstream effects of ER stress are highlighted in blue. polymerase (Qiagen) using a pairs of primers corresponding to nucleotides 412-431 (CCTTGTAGTTGAGAACCAGG) and 834-853 (GGGGCTTGGTATATATGTGG) of XBP1 cDNA. Amplification started with a first step of 2 min at 94 1C, continued with a second step made of 40 cycles 94 1C for 30 s, 55 1C for 30 s, and 72 1C for 60 s, and finished with a last step of 10 min at 72 1C. PCR products were run on a 3% agarose gel.
Western blotting
Cells were treated with PRIMA-1 MET for 16-24 h and collected and lysed. Equal amount of total proteins were separated by electrophoresis on an SDS-polyacrylamide gel, and then transferred on a nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen). Anti-b-actin (AC-15, Sigma, Stockholm, Sweden), anti-p53 (FL393, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-14-3-3 (H8, Santa Cruz Biotechnology), anti-Noxa (OP180, Calbiochem, Darmstadt, Germany), and anti-BiP/GRP78 (610978, BD Biosciences, San Jose, CA, USA) antibodies were used. Protein bands were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Pierce, Rockford, IL, USA).
Cell staining
Cells were treated with PRIMA-1 MET for 8 or 24 h at final concentrations ranging from 10 to 75 mM. Cells were fixed in 4% formaldehyde and permeabilized in 0.2% Triton-X. To visualize F-actin, cells were stained with TexasRed-X phalloidin (Invitrogen). All samples were mounted with Vectashied mounting medium with DAPI (Vector laboratories). Images were captured on a Zeiss Axioplan 2 microscope.
Flow cytometry
Cells were treated with PRIMA-1 MET for 48 h, collected, fixed in 70% ethanol, treated with RNase A, stained with propidium iodide and analyzed with a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, CA, USA).
Immunoprecipitation
Cells were treated with PRIMA-1 MET for 6 h, and then collected and incubated for 45 min on ice in lysis buffer. Samples containing equal amount of proteins were precleared by incubating 2 h at 4 1C with Dynabeads protein A (Invitrogen). Supernatants were transferred into new tubes and incubated overnight at 4 1C with anti-BiP/GRP78. Antibodies were then captured by incubating with 10 ml Dynabeads protein A for 1 h on a rotation wheel at 4 1C. Proteins were eluted with 0.1 M citrate pH 3.1 and neutralized with 25 mM NaOH. Eluted samples were separated on a SDS-polyacylamide gel, which were then stained with the Silver Quest kit (Invitrogen) according to the manufacturer's instructions.
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